prasinezumab

AssetAlso PRX002, RG-7935, RO-7046015

Targets the C-terminus of alpha-synuclein.

Stage: Phase 3
Modality: Antibody
Target: SNCA; 1
Indication: 1
Trial: 2
Developers

Indications

1

Parkinson's disease
Phase 3, prothena.com, 10 Oct 2026

In the full profile

Targets and what it contains2
Owner and partners3
Trials1
Evidence for its targets2
Competitors12
Aging relevance1
Signals2

Every asset’s record: target, stage, trials and the evidence behind it.